Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI571 in Ph+ CML Resistant or Intolerant to Interferon-alpha
NCT00511303Phase 2Completed
- Sponsor
- Alma Mater Studiorum – Università di Bologna
- Start
- Aug 2000
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of imatinib in chronic myeloid leukemia (CML), sponsored by Alma Mater Studiorum – Università di Bologna. Started Aug 2000; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00511303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00511303.